HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
t0rP2p740Xzr0NBG